CSM Corbion NV

Corbion signed US$ 170 million US Private Placement Notes

Corbion signed US$ 170 million US Private Placement Notes

Corbion has signed a US Private Placement (USPP) Notes program with 5 institutional investors. The issuance of US$ 170 million under this program consists of two tranches of each US$ 85 million with maturities of 7 and 10 years with a fixed interest rate of 2.12% and 2.43%.

The proceeds will be used to repay borrowings under the current € 300 million Revolving Credit Facility and for general corporate purposes. 

This program will further optimise the maturity profile of Corbion’s outstanding debt, and will provide maximum flexibility under the current € 300 million Revolving Credit Facility.

Attachment

EN
30/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Corbion NV

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List How to start 2026?

How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...

Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Livio Luyten
  • Thomas Couvreur
  • Wim Hoste
Wim Hoste
  • Wim Hoste

Corbion Strategy update shows increased focus, upgrade to BUY

Corbion's BRIGHT 2030 strategy update revealed an increasing focus on clean label Food Ingredients, Nutrition and Biomedical Polymers/Pharma. Biochemicals are being de-prioritized and the strategic ownership review on PLA will most likely result in an exit. Financial targets include a 3-6% annual organic sales growth target and a c 2pp increase in the adjusted EBITDA margin by 2028. A disciplined approach on capex is expected to result in an average 8% FCF yield in the coming years with a streng...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch